WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers. (Q40045662)
Jump to navigation
Jump to search
scientific article published on 22 October 2007
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers. |
scientific article published on 22 October 2007 |
Statements
WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers (English)
Che-Jen Hsiao
Ya-Ling Chan
Cho-Hwa Liao
Chien-Hua Lee
Ping-Chiang Lyu
22 October 2007